ArticleHuman pathology2013
Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma.
Article in Human pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 3 syntheses or guidelines pooled it, 174 citations in OpenAlex.
- Predictive Values of Pathological and Clinical Risk Factors for Positivity of Sentinel Lymph Node Biopsy in Thin Melanoma: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Pooled it
- PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis.PloS one · 2016Pooled it
- Heme Oxygenase-1 Differentially Controls Pigmentation in Physiological and Pathological Melanogenesis.Pigment cell & melanoma research · 2026Article
- Article
- Pmel17 Deficiency Affects Melanogenesis and Promotes Tumor Vascularization.International journal of molecular sciences · 2026Article
- Melanoma cells suppress mast cell function via a melanin-dependent mechanism.The FEBS journal · 2025Article
- Rethinking Lymphadenectomy in Cutaneous Melanoma: From Routine Practice to Selective Indication: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- The Journey of Sentinel Lymph Node Biopsy in Cutaneous Melanoma: A Brief Narrative Review from Scalpel to Smart Tech.Medicina (Kaunas, Lithuania) · 2025Review
- Article
- Role of ELP6 in tumour progression and impact on ERK1/2 signalling pathway inhibitors in skin cutaneous melanoma.Oncology letters · 2025Article
- PPAR-γ in Melanoma and Immune Cells: Insights into Disease Pathogenesis and Therapeutic Implications.Cells · 2025Review
- Small-Molecule Tyrosinase Inhibitors for Treatment of Hyperpigmentation.Molecules (Basel, Switzerland) · 2025Review
- Understanding Mechanisms and Key Factors Influencing Melanogenesis for the Management of Melasma: An Updated Review.Current pharmaceutical biotechnology · 2025Review
- drexml: A command line tool and Python package for drug repurposing.Computational and structural biotechnology journal · 2024Article
- Complex Inhibitory Activity of Pentacyclic Triterpenoids against Cutaneous Melanoma In Vitro and In Vivo: A Literature Review and Reconstruction of Their Melanoma-Related Protein Interactome.ACS pharmacology & translational science · 2024Review
- Recycled melanoma-secreted melanosomes regulate tumor-associated macrophage diversification.The EMBO journal · 2024Article
- Thin Amelanotic and Hypomelanotic Melanoma: Clinicopathological and Dermoscopic Features.Medicina (Kaunas, Lithuania) · 2024Article
- The metabolism of melanin synthesis-From melanocytes to melanoma.Pigment cell & melanoma research · 2024Review
- Review
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Because melanogenesis can affect immune responses to and chemotherapy and radiotherapy for melanoma, we analyzed overall survival and disease-free survival times in melanoma patients in relation to the degree of tumor pigmentation. Clinicopathologic data were obtained from the Oncology Centre, Prof Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland. The overall survival and disease-free survival analyses were performed using the log-rank test, whereas differences between mean/median overall survival and disease-free survival (days) were analyzed using the Student t test. In patients with metastatic disease, those with melanotic melanomas exhibited significantly shorter disease-free survival and overall survival than those with amelanotic lesions. Similarly, melanin-producing lymph node metastases were linked to shorter overall survival and disease-free survival, which was confirmed by a significantly longer mean/median disease-free survival for amelanotic versus melanotic metastases. Melanogenesis shortens overall survival and disease-free survival in patients with metastatic melanoma. Inhibition of melanogenesis appears a rational adjuvant approach to the therapy of metastatic melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.